Abstract
Microbiological response of SARS-CoV-2 to remdesivir in immunocompromised patients has not been evaluated. We present the case of a severely immunocompromised patient with persistent replication of SARS-CoV-2, who required different courses of remdesivir. Short courses of remdesivir might be insufficient in immunocompromised patients due to prolonged viral clearance.
Keywords: COVID-19; Immunosuppression; Lymphoma; Remdesivir; SARS-CoV-2.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Immunosuppression, Remdesivir, lymphoma, 【초록키워드】 SARS-CoV-2, Immunocompromised patients, Immunosuppression, Remdesivir, viral clearance, Immunocompromised patient, Viral, lymphoma, replication of SARS-CoV-2, Course, evaluated, required, 【제목키워드】 Remdesivir, Immunocompromised patient, persistent, replication of SARS-CoV-2, Course, treated,
【저자키워드】 COVID-19, SARS-CoV-2, Immunosuppression, Remdesivir, lymphoma, 【초록키워드】 SARS-CoV-2, Immunocompromised patients, Immunosuppression, Remdesivir, viral clearance, Immunocompromised patient, Viral, lymphoma, replication of SARS-CoV-2, Course, evaluated, required, 【제목키워드】 Remdesivir, Immunocompromised patient, persistent, replication of SARS-CoV-2, Course, treated,
{{{ 추상적인 }}}
면역 저하 환자에서 렘데시비르에 대한 SARS-CoV-2의 미생물학적 반응은 평가되지 않았습니다. 우리는 다른 과정의 렘데시비르가 필요한 심각한 면역 저하 환자의 SARS-CoV-2 복제가 지속되는 사례를 제시합니다. 장기간의 바이러스 제거로 인해 면역 저하 환자의 경우 단기 렘데시비르 투여가 불충분할 수 있습니다.
{{ 키워드: }} 코로나19; 면역억제; 림프종; 렘데시비르; 사스 코로나바이러스 2.